Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors (LIGHT)

January 14, 2016 updated by: Ardea Biosciences, Inc.

A Phase 3 Randomized, Double-Blind, Multicenter, Placebo- Controlled Study to Assess the Efficacy and Safety of Lesinurad Monotherapy Compared to Placebo in Subjects With Gout and an Intolerance or Contraindication to a Xanthine Oxidase Inhibitor

This study will assess the serum uric acid lowering effects and safety of lesinurad compared to placebo in patients who are intolerant or have a contraindication to allopurinol or febuxostat.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Allopurinol is the standard of care for the treatment of gout. In practice, approximately 20% of patients report side effects with allopurinol and 5% discontinue allopurinol due to side effects. Allopurinol can cause gastrointestinal intolerance, such as nausea and diarrhea, which appears to be dosedependent. Rash develops in about 2% of patients treated with allopurinol, and in about 20% of patients treated with allopurinol and ampicillin or amoxicillin. Allopurinol hypersensitivity syndrome remains a major concern among physicians. Mortality has been estimated to be up to nearly one quarter of AHS cases, with multiorgan system disease including hepatocellular changes and renal failure being a serious concern. Allopurinol is also relatively contraindicated for use in combination with 6-mercaptopurine and azathioprine, for which 1/4 to 1/3 lower doses must be given in order to avoid hematologic toxicity. Febuxostat, in clinical trials, has shown a similar AE profile to allopurinol. Liver function abnormalities, nausea, arthralgia and rash were the most commonly reported AEs. In postmarketing experience, Stevens Johnson Syndrome and hypersensitivity rashes have been reported (febuxostat prescribing information). Withdrawals due to AEs were similar in frequency to allopurinol as well. Relative contraindications in combination with 6-mercaptopurine and azathioprine are similar to allopurinol as well. Lesinurad may be an important therapeutic option for patients who either cannot tolerate or who have a contraindication to the use of allopurinol or febuxostat.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
214

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Australia
      • Tasmania, Australia, 7000
    • Queensland
      • Butterfield, Queensland, Australia, 4029
    • Tasmania
      • Hobart, Tasmania, Australia, 7000
  • Belgium
      • Gozee, Belgium, 6534
      • Kortrijk, Belgium, 8500
      • Yvoir, Belgium, 5530
    • Brussels
      • Anderlecht, Brussels, Belgium, 1070
    • Limburg
      • Genk, Limburg, Belgium, 3600
  • Canada
      • Quebec, Canada, G1V 3M7
    • British Columbia
      • Coquitiam, British Columbia, Canada, V3K 3P4
      • Coquitlam, British Columbia, Canada, V3K 3P4
      • Victoria, British Columbia, Canada, V8V 3N7
    • Ontario
      • London, Ontario, Canada, N6A 5R8
      • Mississauga, Ontario, Canada, L5M 2V8
      • Toronto, Ontario, Canada, M9W 4L6
    • Quebec
      • Rimouski, Quebec, Canada, G5L 8W1
  • Germany
      • Dresden, Germany, 01069
    • Saxony
      • Dresden, Saxony, Germany, 01307
      • Leipzig, Saxony, Germany, 04109
  • New Zealand
      • Auckland, New Zealand, 1023
      • Auckland, New Zealand, 1010
    • Bay of Plenty
      • Tauranga, Bay of Plenty, New Zealand, 3143
  • South Africa
      • Durban, South Africa, 4092
      • Pretoria, South Africa, 0002
      • Rondebosch, South Africa, 7700
      • Stellenbosch, South Africa, 7600
      • Thabazimbi, South Africa, 0380
  • United States
    • Alabama
      • Birmingham, Alabama, United States, 35294
      • Birmingham, Alabama, United States, 35211
    • Arizona
      • Glendale, Arizona, United States, 85308
      • Phoenix, Arizona, United States, 85050
      • Tucson, Arizona, United States, 85724
    • Arkansas
      • Jonesboro, Arkansas, United States, 72401
      • Little Rock, Arkansas, United States, 72205
    • California
      • Anaheim, California, United States, 92805
      • Carmichael, California, United States, 95608
      • Covina, California, United States, 91723
      • Huntington Park, California, United States, 90255
      • Irvine, California, United States, 92618
    • Colorado
      • Colorado Springs, Colorado, United States, 80922
      • Denver, Colorado, United States, 80220
      • Denver, Colorado, United States, 80230
      • Englewood, Colorado, United States, 80113
    • Connecticut
      • Milford, Connecticut, United States, 06460
      • Trumbull, Connecticut, United States, 06611
    • Florida
      • Boynton Beach, Florida, United States, 33472
      • Jacksonville, Florida, United States, 32216
      • Miami, Florida, United States, 33143
      • Miami, Florida, United States, 33135
      • Plant City, Florida, United States, 33563
      • Port Orange, Florida, United States, 32127
      • Tampa, Florida, United States, 33607
      • Winter Haven, Florida, United States, 33880
    • Georgia
      • Newman, Georgia, United States, 30265
    • Hawaii
      • Honolulu, Hawaii, United States, 96814
    • Idaho
      • Meridian, Idaho, United States, 83646
    • Illinois
      • Chicago, Illinois, United States, 60624
    • Kentucky
      • Elizabethtown, Kentucky, United States, 42701
      • Lexington, Kentucky, United States, 40504
      • Louisville, Kentucky, United States, 40213
    • Louisiana
      • Metairie, Louisiana, United States, 70006
    • Michigan
      • South Traverse, Michigan, United States, 49684
    • Mississippi
      • Jackson, Mississippi, United States, 39202
      • Olive Branch, Mississippi, United States, 38654
    • Missouri
      • Southfield, Missouri, United States, 48034
      • Washington, Missouri, United States, 63090
    • New Mexico
      • Albuquerque, New Mexico, United States, 87102
      • Albuquerque, New Mexico, United States, 87106
    • New York
      • Brooklyn, New York, United States, 11201
      • Hartsdale, New York, United States, 10530
      • New Windsor, New York, United States, 12553
      • New York, New York, United States, 10016
    • North Carolina
      • Hickory, North Carolina, United States, 28602
      • Raleigh, North Carolina, United States, 27612
      • Winston-Salem, North Carolina, United States, 27103
    • North Dakota
      • Fargo, North Dakota, United States, 58103
    • Ohio
      • Cincinnati, Ohio, United States, 45242
      • Cincinnati, Ohio, United States, 45224
      • Middleburgh Heights, Ohio, United States, 44130
      • Perrysburgh, Ohio, United States, 43551
      • Willoughby Hills, Ohio, United States, 44904
    • Oklahoma
      • Norman, Oklahoma, United States, 73069
    • Pennsylvania
      • Jenkintown, Pennsylvania, United States, 19046
      • Lancaster, Pennsylvania, United States, 17601
      • Lansdale, Pennsylvania, United States, 19446
      • Pittsburgh, Pennsylvania, United States, 15237
      • Reading, Pennsylvania, United States, 19606
      • Sellersville, Pennsylvania, United States, 18960
    • South Carolina
      • Myrtle Beach, South Carolina, United States, 29588
      • Rock Hill, South Carolina, United States, 29732
      • Spartanburg, South Carolina, United States, 29303
    • Tennessee
      • Brentwood, Tennessee, United States, 37027
      • Spring Hill, Tennessee, United States, 37174
    • Texas
      • Dallas, Texas, United States, 75235
      • Houston, Texas, United States, 77098
      • San Antonio, Texas, United States, 78229
      • Victoria, Texas, United States, 77901
    • Utah
      • South Bountiful, Utah, United States, 84010
      • West Jordon, Utah, United States, 84088
      • West Layton, Utah, United States, 84041
    • Virginia
      • Chesapeake, Virginia, United States, 23320
      • Richmond, Virginia, United States, 23235
      • Suffolk, Virginia, United States, 23435
    • Washington
      • Seattle, Washington, United States, 98104
      • Spokane, Washington, United States, 99208
    • West Virginia
      • Morgantown, West Virginia, United States, 26505

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

18 years to 85 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Subject is able to understand the study procedures, the risks involved and willing to provide written informed consent before the first study related activity.
  • Subject meets the diagnosis of gout as per the American Rheumatism Association Criteria for the Classification of Acute Arthritis of Primary Gout.
  • Subject has an sUA level ≥ 6.5 mg/dL at the Screening and Day -7 Visits.
  • Subject must be able to take gout flare prophylaxis with colchicine or NSAID (including Cox-2 selective NSAID) ± PPI.
  • Subject has a history (either by medical record or subject interview) of intolerance or a contraindication to either allopurinol or febuxostat.
  • Body mass index (BMI) < 45 kg/m2

Exclusion Criteria:

  • Subject who is taking any other approved urate-lowering medication that is indicated for the treatment of gout at the Screening Visit.
  • Subject with a documented history or suspicion of kidney stones.
  • Subject who is pregnant or breastfeeding.
  • Subject who consumes more than 14 drinks of alcohol per week (eg, 1 drink = 5 oz [150 mL] of wine, 12 oz [360 mL] of beer, or 1.5 oz [45 mL] of hard liquor).
  • Subject with a history or suspicion of drug abuse within the past 5 years.
  • Subject that requires or may require systemic immunosuppressive or immunomodulatory treatment.
  • Subject with a known or suspected human immunodeficiency virus (HIV) infection.
  • Subject with a positive test for active hepatitis B or hepatitis C infection.
  • Subject with a history of malignancy within the previous 5 years with the exception of non-melanoma skin cancer that has been treated with no evidence of recurrence, treated cervical dysplasia or treated in situ Grade 1 cervical cancer.
  • Subject within the last 12 months with: unstable angina, New York Heart Association class III or IV heart failure, myocardial infarction, stroke, or deep venous thrombosis; or subjects currently receiving anticoagulants.
  • Subject with uncontrolled hypertension.
  • Subject with an estimated creatinine clearance < 30 mL/min.
  • Subject with active peptic ulcer disease requiring treatment.
  • Subject with active liver disease, or hepatic dysfunction.
  • Subject receiving chronic treatment with more than 325 mg salicylates per day.
  • Subject taking valpromide, progabide, or valproic acid.
  • Subject who has received an investigational therapy within 8 weeks or 5 half-lives (whichever is longer) prior to the Screening Visit.
  • Subject with any other medical or psychological condition, which in the opinion of the Investigator and/or Medical Monitor, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements, or to complete the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Placebo Comparator: placebo
Drug: Placebo
Tablets, Placebo QD
Experimental: lesinurad 400 mg
Drug: lesinurad
Tablets, 400 mg QD

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Number of Subjects With an sUA Level That is < 6.0 mg/dL
Time Frame: 6 months
6 months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Ardea Biosciences, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2012

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
October 1, 2013

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
November 1, 2013

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
January 10, 2012

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 11, 2012

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
January 12, 2012

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
February 12, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
January 14, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
July 1, 2015

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • RDEA594-303
  • 2011-003756-39 (EudraCT Number)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Gout

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings